Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders

International Journal of Molecular Sciences

Volumn 10, Issue 6, 2009, Pages 2510-2557

  Choonara, Yahya E ^a   Pillay, Viness ^a   Du Toit, Lisa C ^a   Modi, Girish ^a   Naidoo, Dinesh ^a   Ndesendo, Valence M K ^a   Sibambo, Sibongile R ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

synuclein; Alzheimer's disease; Amyloid protein; Amyotrophic lateral sclerosis; Drug delivery; Huntingtin; Huntington's disease; Neuropathology; Neurotherapeutics; Parkinson's disease; Tau

Indexed keywords

AMANTADINE; BENSERAZIDE; BENZATROPINE; BIPERIDEN; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; LEVODOPA; LOFEPRAMINE; MEMANTINE; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; ORPHENADRINE; PACLITAXEL; PROCYCLIDINE; PROTEINASE INHIBITOR; RILUZOLE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; TRIHEXYPHENIDYL;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ASTHENIA; BLOOD BRAIN BARRIER; BRAIN TUMOR; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; LIVER FUNCTION; NAUSEA; NERVE CELL; NERVE CELL NETWORK; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SIDE EFFECT;

Α-SYNUCLEIN; ALZHEIMER'S DISEASE; AMYLOID-Β PROTEIN; AMYOTROPHIC LATERAL SCLEROSIS; DRUG DELIVERY; HUNTINGTIN; HUNTINGTON'S DISEASE; NEUROPATHOLOGY; NEUROTHERAPEUTICS; PARKINSON'S DISEASE; TAU;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYOTROPHIC LATERAL SCLEROSIS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; DOPAMINE AGENTS; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; TAU PROTEINS;

EID: 67649669728     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms10062510     Document Type: Review

References (280)

1. Cowan, W.M.; Kandel, E.R. Prospects for neurology and psychiatry. J. Am. Med. Assoc. 2001, 285, 594-600. (Pubitemid 32656330)
2. Broom, W.J; Parton, M.J.; Vance, C.A.; Russ, C.; Andersen, P.M.; Hansen,V.; Leigh, P.N.; Powell, J.F.; Al-Chalabi, A.; Shaw, C.E. No association of the SOD1 locus and disease susceptibility or phenotype in sporadic ALS. Neurology 2004, 63, 2419-2422. (Pubitemid 40024368)
3. Lefaucheur, J.P. Motor cortex dysfunction revealed by cortical excitability studies in Parkinson's disease: Influence of antiparkinsonian treatment and cortical stimulation. Clin. Neurophysiol. 2005, 116, 244-253. (Pubitemid 40126927)
4. Ahmed, N.; Ahmed, U.; Thornalley, P.J.; Hager, K.; Fleischer, G.; Münch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J. Neurochem. 2005, 92, 255-263. (Pubitemid 40194017)
5. Ivanoiu, A.; Adam, S.; Van der Linden, M.; Salmon, E.; Juillerat, A.; Mulligan, R.; Seron, X. Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer's disease. J. Neurol. 2005, 252, 47-55. (Pubitemid 40179018)
6. Veldink, J.H.; Kalmijn, S.; van den Berg, L.H. Physical activity and the association with sporadic ALS. Neurol. 2005, 64, 241-245.
7. Lee, V.M.; Goedert, M.; Trojanowski, J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24, 1121-1159. (Pubitemid 32695256)
8. Riemenschneider, M.; Klopp, N.; Xiang, W.; Wagenpfeil, S.; Vollmert, C.; Müller, U.; Förstl, H.; Illig, T.; Kretzschmar, H.; Kurz, A. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 2004, 63, 364-366. (Pubitemid 38971146)
9. Sengoku, R.; Saito, Y.; Ikemura, M.; Hatsuta, H.; Sakiyama, Y.; Kanemaru, K.; Arai, T.; Sawabe, M.; Tanaka, N.; Mochizuki, H.; Inoue, K.; Murayama, S. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J. Neuropathol. Exp. Neurol. 2008, 67, 742-749.
10. Matsuo, E.S.; Shin, R.W.; Billingsley, M.L.; Van deVoorde, A.; O'Connor, M.; Trojanowski, J.Q.; Lee, V.M. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 1994, 13, 989-1002.
11. Lee, E.M.; Kim, J.Y.; Cho, B.R.; Chung, W.K.; Yoon, B.W.; Kim, S.U.; Lee, B.C.; Hwang, W.S.; Moon, S.Y.; Lee, J.S.; Ahn, C. Down-regulation of MHC class I expression in human neuronal stem cells using viral stealth mechanism. Biochem. Biophys. Res. Commun. 2005, 326, 825-835. (Pubitemid 39655994)
12. Shahani, N.; Brandt, R. Functions and malfunctions of the tau proteins. Cell. Mol. Life Sci. 2002, 59, 1668-1680. (Pubitemid 35346971)
13. Rissman, R.A.; Rissman, R.A.; Poon, W.W.; Blurton-Jones, M.; Oddo, S.; Torp, R.; Vitek, M.P.; LaFerla, F.M.; Rohn, T.T.; Cotman, C.W. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 2004, 14, 121-130. (Pubitemid 39071651)
14. King, M.E. Can tau filaments be both physiologically beneficial and toxic? Biochim. Biophys. Acta. 2005, 1739, 260-267. (Pubitemid 40018543)
15. Mattson, M.P.; Sherman, M. Perturbed signal transduction in neurodegenerative disorders involving aberrant protein aggregation. Neuro. Mol. Med. 2003, 4, 109-131. (Pubitemid 37315189)
16. Yuan, J.; Yankner, B.A. Apoptosis in the nervous system. Nature. 2000, 407, 802-809. (Pubitemid 30780744)
17. Morrison, J.H.; Hof, P.R. Life and death of neurons in the aging brain. Sci. 1997, 278, 412-419. (Pubitemid 27454417)
18. Kordower, J.H.; Chu, Y.; Stebbins, G.T.; DeKosky, S.T.; Cochran, E.J.; Bennett, D.; Mufson, E.J. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann. Neurol. 2001, 49, 202-213. (Pubitemid 32157996)
19. Blanchet, P.J. Antipsychotic drug-induced movement disorders. Can. J. Neurol. Sci. 2003, 30, 101-107. (Pubitemid 36389267)
20. Arendt, T. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Prog. Neurobiol. 2001, 71, 283-1248
21. Palop, J.J.; Chin, J.; Mucke, L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006, 443, 768-773.
22. Price, J.L.; Ko, A.I.; Wade, M.J.; Tsou, S.K.; McKeel, D.W.; Morris, J.C. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 2001, 58, 1395-1402. (Pubitemid 32845990)
23. Greffard, S.; Verny, M.; Bonnet, A.M.; Beinis, J.Y.; Gallinari, C.; Meaume, S.; Piette, F.; Hauw, J.J.; Duyckaerts, C. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol. 2006, 63, 584-588.
24. Terry, R.D.; Masliah, E.; Salmon, D.P.; Butters, N.; DeTeresa, R.; Hill, R.; Hansen, L.A.; Katzman, R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30, 572-580.
25. Honig, L.S.; Rosenberg, R.N. Apoptosis and neurologic disease. Am. J. Med. 2000, 108, 317-330.
26. Onteniente, B. Natural and synthetic inhibitors of caspases: Targets for novel drugs. Curr. Drug Targ. CNS Neurol. Disord. 2000, 3, 333-340.
27. Gao, H.M.; Jiang, J.; Wilson, B.; Zhang, W.; Hong, J.S.; Liu, B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 2002, 81, 1285-1297. (Pubitemid 34809262)
28. Calabrese, V.; Scapagnini, G.; Colombrita, C.; Ravagna, A.; Pennisi, G.; Giuffrida, S.A.M.; Galli, F.; Butterfield, D.A. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids. 2003, 25, 437-444. (Pubitemid 38041278)
29. Miledi, R.; Duen, Z.; Martinez-Torres, A.; Kawas, C.H.; Eusebi, F. Microtransplantation of functional receptors and channels from the Alzheimer's brain to frog oocytes. Proc. Natl. Acad. Sci. USA. 2004, 101, 1760-1763. (Pubitemid 38234227)
30. Hwang, D.Y.; Cho, J.S.; Lee, S.H.; Chae, K.R.; Lim, H.J.; Min, S.H.; Seo, S.J.; Song, Y.S.; Song, C.W.; Paik, S.G.; Sheen, Y.Y.; Kim, Y.K. Aberrant expressions of pathogenic phenotype in Alzheimer's disease transgenic mice carrying NSE-controlled APPsw. Exp. Neurol. 2004, 186, 20-32. (Pubitemid 38229902)
31. Mani, R.B. The evaluation of disease modifying therapies in Alzheimer's disease: A regulatory viewpoint. Stat. Med. 2004, 23, 305-314. (Pubitemid 38100643)
32. Bosch, M.; Pineda, J.R.; Suñol, C.; Petriz, J.; Cattaneo, E.; Alberch, J.; Canals, J.M. Induction of GABAergic phenotype in a neural stem cell line for transplantation in an excitotoxic model of Huntington's disease. Exp. Neurol. 2004, 190, 42-58. (Pubitemid 39335705)
33. Goldman, S.A. Directed mobilization of endogenous neural progenitor cells: the intersection of stem cell biology and gene therapy. Curr. Opin. Mol. Ther. 2004, 6, 466-472. (Pubitemid 39386595)
34. Mohapel, P.; Brundin, P. Harnessing endogenous stem cells to treat neurodegenerative disorders of the basal ganglia. Parkinsonism Relat. Disord. 2004, 10, 259-264. (Pubitemid 38757805)
35. Lewin, R. Is your brain really necessary? Science 1980, 210, 1232-1234. (Pubitemid 11178008)
36. Chen, R.; Cohen, L.G.; Hallett, M. Nervous system reorganization following injury. Neurosci. 2002, 111, 761-773. (Pubitemid 34603248)
37. Muchowski, P.J.; Wacker, J.L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 2005, 6, 11-22. (Pubitemid 40052135)
38. Hynd, M.R.; Scott, H.L.; Dodd, P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int. 2004, 45, 583-595. (Pubitemid 38844879)
39. Wyss-Coray, T.; Mucke, L. Inflammation in neurodegenerative disease: A double-edged sword. Neuron 2002, 35, 419-432. (Pubitemid 34879943)
40. Beal, M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 2005, 58, 495-505. (Pubitemid 41377212)
41. Handley, O.J.; Naji, J.J.; Dunnett, S.B.; Rosser, A.E. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin. Sci. 2006, 110, 73-88.
42. Levine, M.S.; Cepeda, C.; Hickey, M.A.; Fleming, S.M.; Chesselet, M.F. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci. 2004, 27, 691-697. (Pubitemid 39335840)
43. Lazarov, O.; Robinson, J.; Tang, Y.P.; Hairston, I.S.; Korade-Mirnics, Z.; Lee, V.M.; Hersh, L.B.; Sapolsky, R.M.; Mirnics, K.; Sisodia, S.S. Environmental enrichment reduces A levels and amyloid deposition in transgenic mice. Cell. 2005, 120, 701-713. (Pubitemid 40343081)
44. Van Dellen, A.; Grote, H.E.; Hannan, A.J. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease. Clin. Exp. Pharmacol. Physiol. 2005, 32, 1007-1019. (Pubitemid 43906809)
45. Mahley, R.W.; Weisgraber, K.H.; Huang, Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl Acad. Sci. 2006, 103, 5644-5651.
46. Bezard, E.; Gross, C.E.; Brotchie, J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 2003, 26, 215-221. (Pubitemid 36412004)
47. Stern, Y. What is cognitive reserve? Theory and research application of the reserve concept. J. Int. Neuropsychol. Soc. 2002, 8, 448-460. (Pubitemid 34296102)
48. Buckner, R.L. Memory and executive function in aging and AD: Multiple factors that cause decline and reserve factors that compensate. Neuron 2004, 44, 195-208. (Pubitemid 39348840)
49. Maguire, E.A.; Valentine, E.R.; Wilding, J.M.; Kapur, N. Routes to remembering: the brains behind superior memory. Nat. Neurosci. 2003, 6, 90-95 (Pubitemid 36026337)
50. Zlokovic, B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005, 28, 202-208. (Pubitemid 40445527)
51. Miller, D.L.; Ortega, S.; Bashayan, O.; Basch, R.; Basilica C. Compensation by fibroblast growth factor 1 (fgf1) does not account for the mild phenotypic defects observed in fgf2 null mice. Mol. Cell. Biol. 2000, 20, 2260-2268. (Pubitemid 30123841)
52. Dono, R.; Texido, G.; Dussel, R.; Ehmke, H.; Zeller, R. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. Embryo J. 1998, 17, 4213-4225. (Pubitemid 28362612)
53. Feldman, B.; Poueymirou, W.; Papaioannou, V. E.; DeChiara, T.M.; Goldfarb, M. Requirement of FGF-4 for post-implantation mouse development. Science 1995, 267, 246-249.
54. Floss, T.; Arnold, H.H.; Braun, T. A role for FGF-6 in skeletal muscle regeneration. Genes Dev. 1997, 11, 2040-2051. (Pubitemid 27369099)
55. Ortega, S.; Ittmann, M.; Tsang, S.H.; Ehrlich, M.; Basilico, C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc. Natl. Acad. Sci. USA. 1998, 95, 5672-5677. (Pubitemid 28224154)
56. Prinz, A.A.; Bucher, D.; Marder, E. Similar network activity from disparate circuit parameters. Nat. Neurosci. 2004, 7, 1345-1352. (Pubitemid 41057757)
57. Whone, A.L.; Watts, R.L.; Stoessl, A.J.; Davis, M.; Reske, S.; Nahmias, C.; Lang, A.E.; Rascol, O.; Ribeiro, M.J.; Remy, P. Slower progression of Parkinsons disease with ropinirole versus levodopa. Ann. Neurol. 2003, 54, 93-101.
58. Evans, D.A. Etimated prevalence of Alzheimer's disease in the United States. Milbank Q. 1990, 68, 267-289.
59. Palop, J.J.; Chin, J.; Mucke, L.A network dysfunction perspective on neurodegenerative diseases. Nature. 2006, 443, 768-773. (Pubitemid 44622680)
60. Heckmann, J.M.; Low, W.C.; de Villiers, C.; Rutherford, S.; Vorster, A.; Rao, H.; Morris, C.M.; Ramesar, R.S.; Kalaria, R.N. Novel presenilin 1 mutation with profound neurofibrillary pathology in an indigenous Southern African family with early-onset Alzheimer's disease. Brain 2004, 127, 133-142. (Pubitemid 38055352)
61. Vazey, K.; Chen, S.; Hughes, M.; Connor, B. Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease. Exp. Neurol. 2006, 199, 384-396. (Pubitemid 43928967)
62. Ende, N.; Chen, R. Human umbilical cord blood cells ameliorate Huntington's disease in transgenic mice. J. Med. 2001, 32, 231-240. (Pubitemid 32899515)
63. Lescaudron, L.; Unni, D.; Dunbar, G.L. Autologous adult bone marrow stem cell transplantation in an animal model of huntington's disease: behavioral and morphological outcomes. Int. J. Neurosci. 2003, 113, 945-956. (Pubitemid 36975650)
64. Newman, M.B.; Davis, C.D.; Borlongan, C.V.; Emerich, D.; Sanberg, P.R. Transplantation of human umbilical cord blood cells in the repair of CNS diseases. Expert Opin. Biol. Ther. 2004, 4, 121-130. (Pubitemid 38200426)
65. Ferri, C.P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M. Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P.R.; Rimmer, E.; Scazufca, M. Global prevalence of dementia: A Delphi consensus study. Lancet 2005, 366, 2112-2117. (Pubitemid 41797645)
66. Andlin-Sobocki, P.; Jönsson, B.; Wittchen, H.U.; Olesen, J. Cost of disorders of the brain in Europe. Eur. J. Neurol. 2005, 12, 1-27. (Pubitemid 40762612)
67. Jönsson, L.; Berr, C. Cost of dementia in Europe. Eur. J. Neurol. 2005, 12, 50-53. (Pubitemid 40755604)
68. Terry, R.D.; Katzman, R. Senile dementia of the Alzheimer type. Ann. Neurol. 1983, 14, 497-506. (Pubitemid 14239716)
69. Kennedy, J.L.; Farrer, L.A.; Andreasen, N.C.; Mayeux, R.; St George-Hyslop, P. The genetics of adult-onset neuropsychiatric disease: Complexities and conundra? Science 2003, 302, 822-826. (Pubitemid 37339615)
70. McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurol. 1984, 34, 939-944. (Pubitemid 14076461)
71. Galasko, D.; Hansen, L.A.; Katzman, R.; Wiederholt, W.; Masliah, E.; Terry, R.; Hill, L.R.; Lessin, P.; Thal, L.J. Clinical neuropathological correlations in Alzheimer's disease and related dementias. Arch. Neurol. 1994, 51, 888-895. (Pubitemid 24286043)
72. Kosunen, O.; Soininen, H.; Paljärvi, L.; Heinonen, O.; Talasniemi, S.; Riekkinen, P.J. Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta. Neuropathol. (Berl) 1991, 185-193.
73. Blennow, K.; Hampel, H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2, 605-613. (Pubitemid 37162569)
74. Cummings, J.L.; Vinters, H.V.; Cole, G.M.; Khachaturian, Z.S. Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998, 51, 2-17. (Pubitemid 28345337)
75. Larson, E.B.; Edwards, J.K.; O'Meara, E.; Nochlin, D.; Sumi, S.M. Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia. J. Gerontol. A Biol. Sci. Med. Sci. 1996, 51, 313-318. (Pubitemid 26394081)
76. Rasmusson, D.X.; Brandt, J.; Steele, C.; Hedreen, J.C.; Troncoso, J.C.; Folstein, M.F. Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis. Assoc. Disord. 1996, 10, 180-188. (Pubitemid 26401914)
77. American Psychiatric Association DSM-IV; Diagnostic and Statistical Manual, 4th Ed., American Psychiatric Association: Washington, DC, USA, 1994.
78. International Classification of Diseases (ICD-10). Classification of Mental and Behavioural Disorders, 10th Ed.; World Health Organization: Geneva, Switzerland, 1992.
79. Petersen, R.C. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 2000, 15, 93-101. (Pubitemid 30340226)
80. Petersen, R.C.; Smith, G.E.; Ivnik, R. J.; Tangalos, E.G.; Schaid, D.J.; Thibodeau, S.N.; Kokmen, E.; Waring, S.C.; Kurland, L.T. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995, 273, 1274-1278.
81. Petersen, R.C.; Smith, G.E.; Waring, S.C.; Ivnik, R.J.; Tangalos, E.G.; Kokmen, E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56, 303-308. (Pubitemid 29120227)
82. Rocchi, A.; Pellegrini, S.; Siciliano, G.; Murri, L. Causative and susceptibility genes for Alzheimer's disease: A review. Brain Res. Bull. 2003, 61, 1-24. (Pubitemid 36682979)
83. Niewöhner, J.; Tannert, C. Gene therapy: Prospective technology assessment in its societal context, 1st ed.; Elsevier Science: Berlin, Germany, 2006.
84. Peterson, J. Immune deficiency and balance disorder result from a single gene defect. Available online: http://www.jax.org/news/balance-gene-defect.html, accessed 2008.
85. Martins, I.C.; Kuperstein, I.; Wilkinson, H.; Maes, E.; Vanbrabant, M.; Jonckheere, W.; Van Gelder, P.; Hartmann, D.; D'Hooge, R.; De Strooper, B.; Schymkowitz, J.; Rousseau, F. Lipids revert inert Aβ-amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 2008, 27, 224-233.
86. Cummings, J.L.; Vinters, H.V.; Cole, G.M.; Khachaturian, Z.S. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998, 51, S2-S17. (Pubitemid 28345337)
87. Schwartz, A.L.; Ciechanover, A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 1999, 50, 57-74. (Pubitemid 29117052)
88. Gotz, J.; Tolnay, M.; Barmettlet, R.; Chen, F.; Probst, A.; Nitsch, R.M. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. Eur. J. Neurosci. 2001, 13, 2131-2140. (Pubitemid 32578799)
89. Lamb, B.T., Bardel, K.A.; Kulnane, L.S.; Anderson, J.J.; Holtz, G.; Wagner, S.L.; Sisodia, S.S.; Hoeger E.J. Amyloid production and deposition in mutant amyloid presursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat. Neurosci. 1999, 2, 695-697. (Pubitemid 30491189)
90. Selkoe, D.J.; Schenk, D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann. Rev. Pharmacol. Toxicol. 2003, 43, 545-584. (Pubitemid 37372653)
91. Lleo, A.; Blesa, R.; Queralt, R.; Ezquerra, M.; Molinuevo, J.L.; Pena-Casanova, J.; Rojo, A.; Oliva, R. Frequency of mutations in the presenilin and amyloid precursor protein genes in earlyonset Alzheimer disease in Spain. Arch. Neurol. 2002, 59, 1759-1763. (Pubitemid 35340486)
92. Cataldo, A.M.; Peterhoff, C.M.; Schmidt, S.D.; Terio, N.B.; Duff, K.; Beard, M.; Mathews, P.M.; Nixon, R.A. Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J. Neuropathol. Exp. Neurol. 2004, 63, 821-830. (Pubitemid 39038504)
93. Grundke-Iqbal, I.; Iqbal, K. Tau pathology generated by over expression of tau. Am. J. Pathol. 1999, 155, 1781-1785.
94. Kosik, K.S.; Crandall, J.E.; Mufson, E.J.; Neve, R.L. Tau in situ hybridization in normal and Alzheimer brain: localization in the somatodendritic compartment. Ann. Neurol. 1989, 26, 352-361. (Pubitemid 19230304)
95. Papasozomenos, S.C. Tau protein immunoreactivity in dementia of the Alzheimer type. I. Morphology, evolution, distribution, and pathogenetic implications. Lab Invest. 1989, 60, 123-137. (Pubitemid 19053525)
96. Brandt, R.; Hundelt, M.; Shahani, N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta. 2005, 1739, 331-354. (Pubitemid 40018549)
97. LaFerla, F.M.; Oddo, S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol. Med. 2005, 11, 170-176. (Pubitemid 40502029)
98. Braak, H.; Braak, E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991a, 1, 213-216.
99. Braak, H.; Braak, E. Neuropathological staging of Alzheimer-related changes. Acta. Neuropathol. (Berl) 1991, 82, 239-259.
100. Shen, Z.X. Brain cholinesterases: I. The clinico-histopathological and biochemical basis of Alzheimer's disease. Med. Hypoth. 2004, 63, 285-297. (Pubitemid 38968735)
101. Selkoe, D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6, 487-498.
102. Zhang, Y.; Hayes, A.; Pritchard, A.; Thaker, U.; Haque, M. S.; Lemmon, H.; Harris, J.; Cumming, A.; Lambert, J.; Chartier-Harlin, M.; St. Clair, D.; Iwatsubo, T.; Mann, D.M.; Lendon, C.L. Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease. Neurosci. Lett. 2004, 362, 99-101. (Pubitemid 38759077)
103. Luchsinger, J.A.; Mayeux, R. Dietary factors and Alzheimer's disease. Lancet Neurol. 2004, 3, 579-587. (Pubitemid 39221925)
104. Schutte, D.L. The evolving role of genomics in shaping care for persons with dementia. Nurs. Clin. North Am. 2004, 39, 581-592. (Pubitemid 39149812)
105. Souder, E.; Beck, C. Overview of Alzheimer's disease. Nurs. Clin. North Am. 2004, 39, 545-559.
106. Annaert, W.; De Strooper, B. A cell biological perspective on Alzheimer's disease. Ann. Rev. Cell Dev. Biol. 2002, 18, 25-51. (Pubitemid 35387344)
107. Tuppo, E.E.; Arias, H. R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 2005, 37, 289-305. (Pubitemid 39330191)
108. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21, 383-421. (Pubitemid 30349107)
109. Liu, B.; Hong, J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 2003, 304, 1-7. (Pubitemid 36008905)
110. Landi, F.; Matteo, C.; Graziano, O.; Andrea, R.; Sergio, T.; Roberto, B. Non-Steroidal Anti- Inflammatory Drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am. J. Geriatr. Psych. 2003, 11, 179-185.
111. Bale, K.R. Neurodegenerative disease research in the 21st century. Drug Disc. Today 2004, 9, 553-556. (Pubitemid 38760178)
112. Rogers, J.T.; Lahiri, D.K. Metal and inflammatory targets for Alzheimer's disease. Curr. Drug Targ. 2004, 5, 535-551. (Pubitemid 39004428)
113. Ghorpade, A. To investigate the role of glial cells in central nervous system inflammation and neurodegeneration. University of Nebraska Medical Center, Department of Pharmacology and Experimental Neuroscience (http://www.unmc.edu/dept/pharmacology/index.cfm?CONREF=68).
114. Dhar, A.; Gardner, J.; Borgmann, K.; Wu, L.; Ghorpade, A. Novel role of TGF-β in differential astrocyte-TIMP-1 regulation: Implications for HIV-1-dementia and neuroinflammation. J. Neurosci. Res. 2006, 83, 1271-1280. (Pubitemid 43668010)
115. Dalle-Donne, I.; Giustarini, D.; Colombo, R.; Rossi, R.; Milzani, A. Protein carbonylation in human diseases. Trends Mol. Med. 2003, 9, 169-176. (Pubitemid 36626706)
116. Mariani, E.; Polidori, M.C.; Cherubini, A.; Mecocci, P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 827, 65-75. (Pubitemid 41551598)
117. Praticò, D. Peripheral biomarkers of oxidative damage in Alzheimer's disease: The road ahead. Neurobiol. Aging 2005, 26, 581-583. (Pubitemid 40228748)
118. Sayre, L.M.; Moreira, P.I.; Smith, M.A.; Perry, G. Metal ions and oxidative protein modification in neurological disease. Ann. Ist. Super. Sanita 2005, 41, 143-164. (Pubitemid 43169859)
119. Hynd, M.R.; Scott, H.L.; Dodd, P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int. 2004, 45, 583-595. (Pubitemid 38844879)
120. Siesjö, B.K. Cell damage in the brain: A speculative synthesis. J. Cereb. Blood Flow Metab. 1981, 1, 155-185. (Pubitemid 12250016)
121. Paschen, W. Role of calcium in neuronal cell injury: Which subcellular compartment is involved? Brain Res. Bull. 2000, 53, 409-413. (Pubitemid 32000817)
122. Katayama, T.; Imaizumi, K.; Manabe, T.; Hitomi, J.; Kudo, T.; Tohyama, M. Induction of neuronal death by ER stress in Alzheimer's disease. J. Chem. Neuroanat. 2004, 28, 67-78. (Pubitemid 39198955)
123. Schröder, M.; Kaufman, R.J. ER stress and the unfolded protein response. Mutat. Res. 2005, 569, 29-63. (Pubitemid 39643256)
124. Rego, A.C.; Oliveira, C.R. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem. Res. 2003, 28, 1563-1574. (Pubitemid 37193539)
125. LaFerla, F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 2002, 3, 862-872. (Pubitemid 135706704)
126. Pereira, C.; Agostinho, P.; Moreira, P.I.; Cardoso, S.M.; Oliveira, C.R. Alzheimer's disease associated neurotoxic mechanisms and neuroprotective strategies. Curr. Drug Targ. CNS Neurol. Disord. 2005, 4, 383-403. (Pubitemid 41086757)
127. Hamanaka, H.; Katoh-Fukui, Y.; Suzuki, K.; Kobayashi, M.; Suzuki, R.; Motegi, Y.; Nakahara, Y.; Takeshita, A.; Kawai, M.; Ishiguro, K.; Yokoyama, M.; Fujita, S.C. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Human Mol. Gen. 2000, 9, 353-361. (Pubitemid 30098728)
128. Combarros, O.; Alvarez-Arcaya, A.; Sánchez-Guerra, M.; Infante, J.; Berciano, J. Candidate gene association studies in sporadic Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2002, 14, 41-54. (Pubitemid 34621580)
129. Loo, D.T.; Copani, A.; Pike, C.J.; Whittemore, E.R.; Walencewicz, A.J.; Cotman, C.W. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA 1993, 90, 7951-7955. (Pubitemid 23260832)
130. Su, J.H.; Anderson, A.J.; Cummings, B.J.; Cotman, C.W. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 1994, 5, 2529-2533.
131. Smale, G.; Nichols, N.R.; Brady, D.R.; Finch, C.E.; Horton, W.E. Jr. Evidence for apoptotic cell death in Alzheimer's disease. Exp. Neurol. 1995, 133, 225-230.
132. Sastry, P.S.; Rao, K.S. Apoptosis and the nervous system. J. Neurochem. 2000, 74, 1-20.
133. Chang, W.P.; Chang, W.; Koelsch, G.; Wong, S.; Downs, D.; Huining, D.A.; Weerasena, V.; Gordon, B.; Devasamudram, T.; Bilcer, G.; Ghosh, A.K.; Tang, J. In vivo inhibition of Aβ production by Memapsin 2 (β-secretase) inhibitors. J. Neurochem. 2004, 89, 1409-1416. (Pubitemid 38802662)
134. Jorda, E.G.; Verdaguer, E.; Jiménez, A.; Canudas, A.M.; Rimbau, V.; Camps, P.; Muñoz- Torrero, D.; Camins, A.; Palls, M. (+/-)-huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration. J. Alzheimers Dis. 2004, 6, 577-583. (Pubitemid 40164163)
135. Farlow, M.R.; Lilly, M.L. Rivastigmine: An open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr. 2005, 5, 3.
136. National Institute on Aging (NIA). Evaluation of galantamine in the treatment of AD. Available online: http://clinicaltrials.gov/ct2/show/ NCT00000172?term=Alzheimer's+Disease&rank=51, accessed 2008.
137. Masterman, D. Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias. Clin. Geriatr. Med. 2004, 20, 59-68. (Pubitemid 38221463)
138. Schneider, L.S. AD2000: donepezil in Alzheimer's disease. Lancet 2004, 363, 2100-2101. (Pubitemid 38844146)
139. Reisberg, B.; Doody, R.; Stöffler, A.; Schmitt, F.; Ferris, S.; Jörg-Möbius, H. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2003, 348, 1333-1341.
140. Winblad, B.; Poritis, N. Memantine in severe dementia: results of the 9M-BEST Study (benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry 1999, 14, 135-146. (Pubitemid 29110331)
141. Rosenberg, P.B. Clinical aspects of inflammation in Alzheimer's disease. Int. Rev. Psychiatry 2005, 17, 503-514. (Pubitemid 43086677)
142. Tabira, T. Vaccination therapy for Alzheimer's disease. Brain Nerve 2007, 59, 375-382.
143. Schenk, D.; Seubert, P.; Ciccarelli, B. Immunization with amyloid- beta attenuates Alzheimerdisease- like pathology in the PDAPP mouse. Nature 1999, 400, 173-177. (Pubitemid 29327547)
144. Jeyarasasingam, G.; Tompkins, L.; Quik, M. Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience 2002, 109, 275-285. (Pubitemid 34098968)
145. Conley, S.C.; Kirchner, J.T. Parkinson's disease-the shaking palsy, underlying factors, diagnostic considerations, and clinical course. Postgrad. Med. 1999, 106, 39-42. (Pubitemid 29327707)
146. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2, 492-501.
147. Hashimoto, M.; Kawahara, K.; Bar-On, P.; Rockenstein, E.; Crews, L.; Masliah, E. The role of α- synuclein assembly and metabolism in the pathogenesis of lewy body disease. J. Mol. Neurosci. 2004, 24, 343-352. (Pubitemid 41389374)
148. Hofer, A.; Gasser, T. New aspects of genetic contributions to Parkinson's disease. J. Mol. Neurosci. 2004, 24, 417-424. (Pubitemid 41389378)
149. Schulz, J.B.; Lindenau, J.; Seyfried, J.; Dichgans, J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 2001, 267, 4904-4911.
150. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.Y.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. α- synuclein in lewy bodies. Nature 1997, 388, 839-840. (Pubitemid 27377048)
151. Wirths, O.; Bayer, T.A. Alpha-synuclein, Abeta and Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psych. 2003, 27, 103-108.
152. Snyder, H.; Wolozin, B. Pathological proteins in Parkinson's disease: focus on the proteasome. J. Mol. Neurosci. 2004, 24, 425-442. (Pubitemid 41389379)
153. Nobutaka, N.; Yoshikun, M. Familial Parkinson's disease based on the single gene defects. A key to the understanding the pathogenesis for nigral degeneration in sporadic Parkinson's disease. Juntendo Med. J. 2001, 47, 53-70.
154. Braak, H.; Del-Tredici, K.; Rub, U.; de Vos, R.A.; Jansen-Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24, 197-211. (Pubitemid 36007810)
155. Jellinger, K.A.; Mizuno, Y. Parkinson disease. In Neurodegeneration and Dementias; Dickson, D.W., Ed.; ISN Press: Los Angeles, USA, 2003.
156. Bernheimer, H.; Birkmayer, W.; Hornykiewicz, O.; Jellinger, K.; Seitelberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20, 415-455.
157. Rinne, J.O.; Nurmi, E.; Ruottinen, H.M.; Bergman, J.; Eskola, O.; Solin, O. F-18FDOPA and F- 18CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse 2001, 40, 193-200. (Pubitemid 32322212)
158. Blandini, F.; Nappi, G.; Tassorelli, C.; Martignoni, E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol.
159. Chase, T.N.; Oh, J.D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. 2000, 47, 122-129 (Pubitemid 30192017)
160. Bezard, E.; Brotchie, J.M.; Gross, C.E. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nat. Rev. Neurosci. 2001, 2, 577-588. (Pubitemid 33679831)
161. Parent, A.; Parent, M.; Levesque, M. Basal ganglia and Parkinson disease: An anatomical perspective. Neurosci. News 1999, 2, 19-26. (Pubitemid 29420596)
162. Freeman, A.; Ciliax, B.; Bakay, R.; Daley, J.; Miller, R.D.; Keating, G.; Levey, A.; Rye, D. Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models. Ann. Neurol. 2001, 50, 321-329. (Pubitemid 32848734)
163. th Ed.; Jankovic, J.J., Tolosa, E., Eds.; Lippincott Williams and Wilkins: Philadelphia, USA, 2002, pp. 270-290.
164. Winderickx, J.; Delay, C.; De Vos, A.; Klinger, H.; Pellens, K.; Vanhelmont, T.; Van Leuven, F.; Zabrocki, P. Protein folding diseases and neurodegeneration: Lessons learned from yeast. Mol. Cell Res. 2008, 1783, 1381-1395.
165. Bartzokis, G.; Tishler, T.A.; Shin, I.S.; Lu, P.H.; Cummings, J.L. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann. New York Acad. Sci. 2004, 1012, 224-236. (Pubitemid 38453528)
166. Bridge, M.H.; Williams, E.; Lyons, M.E.; Tipton, K.F.; Linert, W. Electrochemical investigation into the redox activity of Fe(II)/Fe(III) in the presence of nicotine and possible relations to neurodegenerative diseases. Biochim. Biophys. Acta. 2004, 690, 77-84. (Pubitemid 39157357)
167. Ostrerova-Golts, N.; Petrucelli, L.; Hardy, J.; Lee, J.M.; Farer, M.; Wolozin, B. The A53T α- synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 2000, 20, 6048-6054. (Pubitemid 30658398)
168. Halliwell, B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging. 2000, 18, 685-716.
169. Outeiro, T.F.; Lindquist, S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003, 302, 1772-1775. (Pubitemid 37505742)
170. McLean, P.J.; Kawamata, H.; Hyman, B.T. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome-sensitive inclusions in primary neurons. Neuroscience 2001, 104, 901-912. (Pubitemid 32607439)
171. Jo, E.; McLaurin, J.; Yip, C.M.; St. George-Hyslop, P.; Fraser, P.E. α-synuclein membrane interactions and lipid specificity. J. Biol. Chem. 2000, 275, 34328. (Pubitemid 30819201)
172. Seibyl, J.; Jennings, D.; Tabamo, R.; Marek, K. Neuroimaging trials of Parkinson's disease progression. J. Neurol. 2004, 251, 9-13. (Pubitemid 39506526)
173. Simuni, T.; Hurtig, H. Levodopa: 30 years of progress. In Parkinson's Disease Diagnosis and Clinical Management; Factor, S.A., Weiner, W.J., Eds.; Demos Medical Publishing, Inc.: Philadelphia, USA, 2000.
174. Albin, R.L.; Frey, K.A. Initial agonist treatment of Parkinson disease. Neurol. 2003, 60, 390-394. (Pubitemid 36188231)
175. Mercuri, N.B.; Benardi, G. The 'magic' of L-dopa: Why is it the gold standard Parkinson's disease therapy? Trends Pharmacol. Sci. 2005, 26, 341-344. (Pubitemid 40848494)
176. Thanvi, B.R.; Lo, T.C. Long term motor complications of levodopa: Clinical features, mechanisms, and management strategies. Postgrad. Med. J. 2004, 80, 452-458. (Pubitemid 39108037)
177. Woitalla, D.; Müller, T.; Benz, S.; Horowski, R.; Przuntek, H. Transdermal lisuride delivery in the treatment of Parkinson's disease. J. Neural. Transm. Suppl. 2004, 68, 89-95. (Pubitemid 39215441)
178. Siddiqui, M.A.; Plosker, G.L. Rasagiline. Drugs Aging 2005, 22, 83-91.
179. Kim, M.S.; Lee, J.I.; Lee, W.Y.; Kim, S.E. Neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson's disease. Phytother. Res. 2004, 18, 663-666. (Pubitemid 39329718)
180. Mochizuki, H. Future of gene therapy for Parkinson's disease. Rinsho Shinkeigaku 2004, 44, 948-950. (Pubitemid 40013404)
181. Levy, Y.S.; Stroomza, M.; Melamed, E.; Offen, D. Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease. J. Mol. Neurosci. 2004, 24, 353-386.
182. Karimi and Eftekharpour. Fehlings lab, McEwen Centre for Regenerative Medicine. Available online: www.mcewencentre.com/res-prog-scnd.asp, accessed 2009.
183. O'Brien, J.T.; Fenwick, J.; Williams, E.D.; Firbank, M.; Aarsland, D.; McKeith, I.G. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with lewy bodies. Arch. Neurol. 2004, 61, 919-925. (Pubitemid 38747333)
184. McKeith, I.; O'Brien, J.; Walker, Z.; Tatsch, K. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study. Lancet Neurol. 2004, 6, 305-313.
185. Walkinshaw, G.; Waters, C.M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 1995, 95, 2458-2464.
186. Whone, A.L.; Moore, R.Y.; Piccini, P.P.; Brooks, D.J. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann. Neurol. 2003, 53, 206-213. (Pubitemid 36164002)
187. Brooks, D.J.; Torjanski, N.; Burn, D.J. Ropinirole in the symptomatic treatment of Parkinson's disease. J. Neural. Transm. Suppl. 1995, 45, 231-238.
188. Uitti, R.J.; Rajput, A.H.; Ahlskog, J.E.; Offord, K.P.; Schroeder, D.R.; Ho, M.M.; Prasad, M.; Rajput, A.; Basran, P. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996, 46, 1551-1556. (Pubitemid 26185770)
189. Ebadi, M.S.; Pfeiffer, R. Amantadine neuroprotective effect on PD. Parkinson's Dis. 2005, 686.
190. Münchau, A.; Bhatia, K.P. Pharmacological treatment of Parkinson's disease. Postgrad. Med. J. 2000, 76, 602-610. (Pubitemid 30784301)
191. Oertel, W.H.; Quinn, N.P. Neurological Disorders Course and Treatment. In Parkinsonism; Brandt, T., Caplan, L.R., Dichgans, J., Eds.; Academic Press: San Diego, USA 1996, pp. 715-772.
192. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neurol. 1997, 42, 747-755 (Pubitemid 27481547)
193. Churchyard, A.; Mathias, C.J.; Boonkonchuen, P.; Lees, A. Autonomic effects of selegeline: Possible cardiovascular toxicity in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1997, 63, 228-234. (Pubitemid 27388974)
194. Duvoisin, R.C. Cholinergic-anticholinergic antagonisms in parkinsonism. Arch. Neurol. 1967, 17, 124-136.
195. Pondal, M.; Del Ser, T.; Berjemo, F. Anticholinergic therapy and dementia in patients with Parkinson's disease. J. Neurol. 1996, 243, 543-546. (Pubitemid 26239709)
196. Kaakkola, S.; Gordin, A.; Männisto, P.T. General properties and clinical possibilities of new selective inhibitors of catechol-o- methyltransferase. Gen. Pharmacol. 1994, 25, 813-824. (Pubitemid 24295641)
197. Keräenen, T.; Gordin, A.; Harjola, V.P.; Karlsson, M.; Korpela, K.; Pentikäinen, P.J.; Rita, H.; Seppälä, L.; Wikberg, T. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neuropharmacol. 1993, 16, 145-156. (Pubitemid 23090692)
198. Shults, C.W.; Oakes, D.; Kieburtz, K.; Beal, F.; Haas, R.; Plumb, S.; et al. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch. Neurol. 2002, 59, 1541-1550.
199. Freed, C.R.; Greene, P.E.; Breeze, R.E., Curt R.; Tsai, W.; DuMouchel, W.; Kao, R.; Dillon, S.; Winfield, H.; Culver, S.; Trojanowski, J.Q.; Eidelberg, D.; Fahn, S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344, 710-719. (Pubitemid 32204988)
200. Kopyov, O.V.; Jacques, D.S.; Lieberman, A.; Duma, C.M.; Rogers, R.L. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Exp. Neurol. 1997, 146, 536-545. (Pubitemid 27381861)
201. Lopez-Lozano, J.; Bravo, G.; Brera, B.; Dargallo, J.; Salmeán, J.; Uría, J.; Insausti, J.; Millán, I. Long-term follow-up in 10 Parkinson's disease patients subjected to fetal brain grafting into a cavity in the caudate nucleus: The Clinica Puerta de Hierro experience. CPH Neural Transplantation Group. Transplant Proc. 1995, 27, 1395-1400.
202. Olanow, C.W.; Goetz, C.G.; Kordower, J.H.; Stoessl, A.J.; Sossi, V.; Brin, M.F.; Shannon, K.M.; Nauert, G.M.; Perl, D.P.; Godbold, J.; Freeman, T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54, 403-414. (Pubitemid 37072046)
203. McGuire, D.; Garrison, L.; Miller, R.G. Relationship of the Tufts Quantitative Neuromuscular Exam(TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. Neurol. 1996, 46, 1442-1444. (Pubitemid 26159310)
204. Ritchie, K.; Kildea, D. Is senile dementia 'age-related' or 'ageing-related'? Evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 1995, 346, 931-934.
205. Bobowick, A.R.; Brody, J.A. Epidemiology of motor-neuron diseases. N. Engl. J. Med. 1973, 288, 1047-1055.
206. Baldereschi, M.; Di Carlo, A.; Rocca, W.A.; Vanni, P.; Maggi, S.; Perissinotto, E.; Grigoletto, F.; Amaducci, L.; Inzitari, D. Parkinson's disease and parkinsonism in a longitudinal study: Two- fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000, 55, 1358-1363.
207. Li, T.M.; Alberman, E.; Swash, M. Clinical features and associations of 560 cases of motor neuron disease. J. Neurol. Neurosurg. Psychiatry. 1990, 53, 1043-1045.
208. Brooks, B.R. Risk factors in the early diagnosis of ALS: North American epidemiological studies. ALS Care Study Group. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000, 1, 19-26.
209. Rowland, L.P. Diagnosis of amyotrophic lateral sclerosis. J. Neurol. Sci. 1998, 160, 6-24. (Pubitemid 28522512)
210. Mulder, D.W.; Howard, F.M. Patient resistance and prognosis in amyotrophic lateral sclerosis. MayoClin. Proc. 1976, 51, 537-541.
211. Gubbay, S.S.; Kahana, E.; Zilber, N.; Cooper, G.; Pintov, S.; Leibowitz, Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J. Neurol. 1985, 232, 295-300. (Pubitemid 15240721)
212. Chen, L.C.; Smith, A.; Ben, Y.; Zukic, B.; Ignacio, S.; Moore, D.; Lee, N. Temporal gene expression patterns in G93A/SOD1 mouse. Amyotroph. Lateral. Scler. Other Motor Neuron Disord. 2004, 5, 164-171. (Pubitemid 39406516)
213. Andersen, P.M., Sims, K.B.; Xin, W.W.; Kiely, R.; O'Neill, G.; Ravits, J.; Pioro, E.; Harati, Y.; Brower, R.D.; Levine, J.S.; Heinicke, H.U.; Seltzer, W.; Boss, M.; Brown, R.H. Jr. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: A decade of discoveries, defects and disputes. Amyotroph. Lateral. Scler. Other Motor Neuron Disord. 2003, 4, 62-73. (Pubitemid 36874774)
214. Rothstein, J.D.; Martin, L.J.; Kuncl, R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Eng. J. Med. 2002, 326, 1464-1468.
215. Hayashi, M.; Araki, S.; Arai, N.; Kumada, S.; Itoh, M.; Tamagawa, K.; Oda, M.; Morimatsu, Y. Oxidative stress and disturbed glutamate transport in spinal muscular atrophy. Brain Dev. 2002, 24, 770-775. (Pubitemid 35365934)
216. Spreux-Varoquaux, O.; Bensimon, G.; Lacomblez, L.; Salachas, F.; Pradat, P.F.; Le Forestier, N.; Marouan, A.; Dib, M.; Meininger, V. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J. Neurol. Sci. 2002, 193, 73-78. (Pubitemid 34098937)
217. Guo, H.; Lai, L.; Butchbach, M.E.R.; Stockinger, M.P.; Shan, X.; Bishop, G.A.; Lin, C.G. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum. Mol. Genet. 2003, 12, 2519-2532. (Pubitemid 37220416)
218. Haggstrom, B.; Andersen, P.M.; Hjalmarsson, K.; Binzer, M.; Forsgren, L. Autoimmunity and ALS: Studies on antibodies to acetylcholinesterase in sera. Acta. Neurol. Scand. 1997, 95, 111-114. (Pubitemid 27107091)
219. Weiss, M.D.; Weydt, P.; Carter, G.T. Current pharmacological management of Amyotrophic Lateral Sclerosis and a role for rational polypharmacy. Exp. Opin. Pharmacother. 2004, 5, 1231.
220. Forman, M.S.; Trojanowski J.Q.; Lee, V.M.Y. TDP-43: A novel neurodegenerative proteinopathy. Curr. Opin. Neurobiol. 2007, 17, 548-555.
221. Hasegawa, M.; Arai, T.; Nonaka, T.; Kametani, F.; Yoshida, M.; Hashizume, Y.; Beach, T.G.; Buratti, E.; Baralle, F.; Morita, M.; Nakano, I.; Oda, T.; Tsuchiya, K.; Akiyama, H. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008, 64, 60-70.
222. van den Berg, L.H.; van den Berg, J.P.; Mathus-Vliegen, E.M.; Kampelmacher, M.J.; van Kesteren, R.G.; Jennekens, F.G. The symptomatic treatment of amyotrophic lateral sclerosis. Ned. Tijdschr. Geneeskd. 2004, 148, 513-518. (Pubitemid 38477715)
223. Miller, R.G.; Mitchell, J.D.; Lyon, M.; Moore, D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2007, 1. No. CD001447. DOI: 10.1002/14651858.CD001447.
224. MacDonald, M.E.; Novelletto, A.; Lin, C.; Tagle, D.; Barnes, G.; Bates, G.; Taylor, S.; Allitto, B.; Altherr, M.; Myers, R.; Lehrach, H.; Collins, F.S.; Wasmuth, J.J.; Frontali, M.; Gusella, J.F. The Huntington's disease candidate region exhibits many different haplotypes. Nat. Genet. 1992, 1, 99-103.
225. Jana, N.R., Dikshit, P.; Goswami, A.; Kotliarova, S.; Murata, S.; Tanaka, K.; Nukina, N. Cochaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 2005, 280, 11635-11640 (Pubitemid 40418477)
226. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is unstable on Huntington's disease chromosomes. Cell 1993, 72, 971-983.
227. Rubinsztein, D.C.; Leggo, J.; Coles, R.; Almqvist, E.; Biancalana, V.; Cassiman, J.J.; Chotai, K.; Connarty, M.; Crauford, D.; Curtis, A., et al. Phenotypic characterization of individuals with 30- 40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am. J. Hum. Genet. 1996, 59, 16-22. (Pubitemid 26189723)
228. Sathasivam, K.; Amaechi, I.; Mangiarini, L.; Bates, G.P. Identification of an HD patient with a (CAG)180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage. Hum. Genet. 1997, 99, 692-695.
229. Lin, B.; Nasir, J.; MacDonald, H.; Hutchinson, G.; Graham, R.K.; Rommesns, J.M.; Hayden, M.R. Sequence of the murine Huntington's disease gene: evidence for conservation, and polymorphism in a triplet (CCG) repeat alternate splicing. Hum. Mol. Genet. 1994, 3, 85-92. (Pubitemid 24038149)
230. Baxendale, S.; Abdulla, S.; Elgar, G.; Buck, D.; Berks, M.; Micklem, G.; Durbin, R.; Bates, G.; Brenner, S.; Beck, S.; Lehrach, H. Comparative sequence analysis of the human and puffer fish Huntington's disease gene. Nat. Genet. 1995, 10, 67-75.
231. Wang, J.; Gines, S.; MacDonald, M.E.; Gusella, J.F. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci. 2005, 6, 1. (Pubitemid 40177061)
232. Trushina, E.; McMurray, C.T. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007, 145, 1223-1248. (Pubitemid 46602738)
233. Myers, R.H.; Vonsattel, J.P.; Paskevich, P.A., Kiely, D.K.; Stevens, T.J.; Cupples, L.A.; Richardson, E.P., Jr.; Bird, E.D. Decreased neuronal and increased oligo dendroglial densities in Huntington's disease caudate nucleus. J. Neuropathol. Exp. Neurol. 1991, 50, 729-742.
234. de la Monte, S.M.; Vonsattel, J.P.; Richardson, E.P., Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatumin Huntington's disease. J. Neuropathol. Exp. Neurol. 1988, 47, 516-525. (Pubitemid 18230669)
235. Sathasivam, K.; Amaechi, I.; Mangiarini, L.; Bates, G.P. Identification of an HD patient with a (CAG) 180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage. Hum Genet. 1997, 99, 692-695.
236. Li, Z.; Karlovich, C.A.; Fish, M.P.; Scott, M.P.; Myers, R.M. A putative Drosophila homolog of the Huntington's disease gene. Hum. Mol. Genet. 1999, 8, 1807-1815. (Pubitemid 29423893)
237. Andrade, M.A.; Bork, P. HEAT repeats in the Huntington's disease protein [letter]. Nat Genet. 1995, 11, 115-116.
238. Wanker, E.E.; Rovira, C.; Scherzinger, E.; Hasenbank, R.; Walter, S.; Tait, D.; Colicelli, J.; Lehrach, H. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet.1997, 6, 487-495. (Pubitemid 27116471)
239. Holtzman, D.A.; Yang, S.; Drubin, D.G. Synthetic-lethal interactions identify two novel genes, SLA1 and SLA2, that controls membrane cytoskeleton assembly in Saccharomyces erevisiae. J. Cell Biol. 1993, 122, 635-644. (Pubitemid 23226680)
240. Wesp, A.; Hicke, L.; Palecek, J.; Lombardi, R.; Aust, T.; Munn, A.L.; Riezman, H. End4p/Sla2p interacts with actin-associated proteins for endocytosis in Saccharomyces cerevisiae. Mol. Biol. Cell.1997, 8, 2291-2306. (Pubitemid 27469389)
241. Velier, J.; Kim, M.; Schwarz, C.; Kim, T.W.; Sapp, E.; Chase, K.; Aronin, N.; DiFiglia, M. Wildtype and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 1998, 152, 34-40. (Pubitemid 28366964)
242. Engqvist-Goldstein, A.E.; Kessels, M.M.; Chopra, V.S.; Hayden, M.R.; Drubin, D.G. An actinbinding protein of the Sla2/Huntingtin interacting protein 1family is a novel component of lathrin-coated pits and vesicles. J. Cell Biol.1999, 147, 1503-1518. (Pubitemid 30027405)
243. Li, X. J.; Li, S.H.; Sharp, A.H., Nucifora, F.C. Jr.; Schilling, G.; Lanahan, A.; Worley, P.; Snyder, S.H.; Ross, C.A. A huntingtin-associated protein enriched in brain with implications for pathology. Nature. 1995, 378, 398-402.
244. Block-Galarza, J.; Chase, K.O.; Sapp, E. Fast transport and retrograde movement of huntingtin and HAP 1 in axons. Neuroreport 1997, 8, 2247-2251. (Pubitemid 27319681)
245. Engelender, S.; Sharp, A. H.; Colomer, V., Tokito, M.K.; Lanahan, A.; Worley, P.; Holzbaur, E. L.; Ross, C.A. Huntingtin-associated protein1 (HAP1) interacts with the p150 glued subunit of dynactin. Hum. Mol. Genet.1997, 6, 2205-2212.
246. Giorgini, F.; Guidetti, P.; Nguyen, Q.; Bennett, S.C.; Muchowski, P.J. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 2005, 37, 526-531 (Pubitemid 40617282)
247. Vonsattel, J.P.; Myers, R.H.; Stevens, T.J.; Ferrante, R.J.; Bird, E.D.; Richardson, E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44, 559-577 (Pubitemid 16196286)
248. Adam, O.R.; Jankovic J. Symptomatic treatment of Huntington's disease. Neurotherapeutics 2008, 5, 181-197.
249. Squitieri, F.; Cannella, M.; Porcellini, A.; Brusa, L.; Simonelli, M.; Ruggieri, S.; Short-term effects of olanzapine in Huntington's disease. Neuropsych. Neuropsychol. Behav. Neurol. 2001, 14, 69-72. (Pubitemid 32179139)
250. Laks, J.; Rocha, M.; Capitao, C.; Domingues, R.C.; Ladeia, G.; Lima, M.; Engelhardt, E. Functional and motor response to low dose olanzapine in Huntington's disease: Case report. Arq. Neuropsiquiatr. 2004, 62, 1092-1094. (Pubitemid 40013114)
251. Grove, V.E. Jr.; Quintanilla, J.; DeVaney, G.T. Improvement of Huntington's disease with olanzapine and valproate. N. Eng. J. Med. 2001, 343, 973-974.
252. Chen, W.X.; Wang, P.; Yan, S.; Li, Y.; Yu, C.; Jiang, L. Acquired hepatocerebral degeneration: A case report. World J. Gastroenterol. 2005, 11, 764-766. (Pubitemid 40220777)
253. Feany, M.B.; Dickson, D.W. Neurodegenerative disorders with extensive tau pathology: A comparative study and review. Ann. Neurol. 1996, 40, 139-148. (Pubitemid 26274548)
254. Umahara, T.; Uchihara, T.; Tsuchiya, K.; Nakamura, A.; Ikeda, K.; Iwamoto, T.; Takasaki, M. Immunolocalization of 14-3-3 isoforms in brains with Pick body disease. Neurosci. Lett. 2004, 371, 215-219. (Pubitemid 39440774)
255. López, C.; Comabella, M.; Al-Zayat, H.; Tintoré, M.; Montalban, X. Altered maturation of circulating dendritic cells in primary progressive MS patients. J. Neuroimmunol. 2006, 175, 183-191. (Pubitemid 43765748)
256. Haslam, C. Managing bladder symptoms in people with multiple sclerosis. Nurs. Times. 2005, 101, 48-50.
257. Trapp, B.D.; Ransohoff, R.; Rudick, R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 1999, 12, 295-302. (Pubitemid 29378163)
258. Oldstone, M.B. Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr. Top. Microbiol. Immunol. 2005, 296, 1-17. (Pubitemid 41667258)
259. Schapira, A.H. Present and future drug treatment for Parkinson's disease. J. Neurol. Neurosurg. Psych. 2005, 76, 1472-1478. (Pubitemid 41531688)
260. Lleo, A.; Greenberg, S.M.; Growdon, J.H. Current pharmacotherapy for Alzheimer's disease. Ann. Rev. Med. 2006, 57, 513-533. (Pubitemid 43262005)
261. Gsell, W.; Jungkunz, G.; Riederer, P. Functional neurochemistry of Alzheimer's disease. Curr. Pharm. Des. 2004, 10, 265-293. (Pubitemid 38072763)
262. Weiner, M. F.; Hynan, L.S.; Parikh, B.; Zaki, N.; White, C.L.; Bigio, E.H.; Lipton, A.M.; Martin- Cook, K.; Svetlik, D.A.; Cullum, C.M.; Vobach, S.; Rosenberg, R.N. Can Alzheimer's disease and dementias with Lewy bodies be distinguished clinically? J. Geriatr. Psych. Neurol. 2003, 16, 245-250. (Pubitemid 37464233)
263. Amatniek, J.C.; Hauser, W.A.; DelCastillo-Castaneda, C.; Jacobs, D.M.; Marder, K.; Bell, K.; Albert, M.; Brandt, J.; Stern, Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006, 47, 867-872. (Pubitemid 44030181)
264. Del Vecchio, R.A.; Gold, L.H.; Novick, S.J.; Wong, G.; Hyde, L.A. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci. Lett. 2004, 367, 164-167. (Pubitemid 39141218)
265. Mark, R.J.; Ashford, J.W.; Goodman, Y.; Mattson, M.P. Anticonvulsants attenuate amyloidpeptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol. Aging 1995, 16, 187-198.
266. Mattson, M.P. Pathways towards and away from Alzheimer's disease. Nat. 2004, 430, 631-639. (Pubitemid 39061671)
267. Palop, J.J.; Chin, J.; Bien-Ly, N.; Massaro, C.; Yeung, B.Z.; Yu, G.; Mucke, L. Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J. Neurosci. 2005, 25, 9686-9693. (Pubitemid 41510909)
268. Palop, J.J.; Jones, B.; Kekonius, L.; Chin, J.; Yu, G.; Raber, J.; Masliah, E.; Mucke, L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl Acad. Sci. 2003, 100, 9572-9577. (Pubitemid 37033969)
269. DeKosky, S.T.; Ikonomovic, M.D.; Styren, S.D.; Beckett, L.; Wisniewski, S.; Bennett, D.A.; Cochran, E.J.; Kordower, J.H.; Mufson, E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 2002, 51, 145-155. (Pubitemid 34111436)
270. Small, D.H. Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease? Trends Neurosci. 2004, 27, 245-249. (Pubitemid 38529951)
271. Dickerson, B.C.; Salat, D.H.; Greve, D.N.; Chua, E.F.; Rand-Giovannetti, E.; Rentz, D.M.; Bertram, L.; Mullin, K.; Tanzi, R.E.; Blacker, D.; Albert, M.S.; Sperling, R.A. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005, 65, 404-411. (Pubitemid 41099803)
272. Yang, Q.; Williams, D.; Owusu-Ababio, G.; Ebube, N.K.; Habib, M.J. Controlled release tacrine delivery system for the treatment of Alzheimer's disease. Drug Deliv. 2001, 8, 93-98. (Pubitemid 32494639)
273. Vinogradov, S.V.; Batrakova, E.V.; Kabanov, A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem. 2004, 15, 50-60. (Pubitemid 38165980)
274. Rice, A.; Michaelis, M.L.; Georg, G.; Liu, Y.; Turunen, B.; Audus, K.L. Overcoming the bloodbrain barrier to taxane delivery for neurodegenerative diseases and brain tumors. J. Mol. Neurosci. 2003, 20, 339-343. (Pubitemid 38146991)
275. Uzan, G. Therapeutic use of stem cells. II. Adult stem cells. Rev. Prat. 2004, 54, 1515-1527. (Pubitemid 39328110)
276. Shoichet, M.; Shoichet lab, McEwen Centre for Regenerative Medicine. Available online: www.mcewencentre.com/res-prog-scnd.asp, accessed 2009.
277. Vernalis (Pty) Ltd. V1512-Treatment of Parkinson's disease. http://www.drugdevelopmenttechnology. com/projects/v1512/. Accessed 2009.
278. Morgan, J.C.; Sethi, K.D. Rotigotine for the treatment of Parkinson's disease. Exp. Rev. Neurother. 2006, 6, 1275-1282.
279. Guldenpfennig, W.M.; Poole, K.H.; Sommerville, K.W.; Boroojerdi, B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin. Neuropharmacol. 2005, 28, 106-110. (Pubitemid 40923407)
280. Watts, R.L.; Jankovic, J.; Waters, C.; Rajput, A.; Boroojerdi, B.; Rao, J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68, 272-276. (Pubitemid 46148338)